. Author manuscript; available in PMC: 2014 Sep 22.

Published in final edited form as: Invest New Drugs. 2008 Aug 20;27(2):159–165. doi: 10.1007/s10637-008-9165-9

Table 4.

Response and survival (intention to treat)

Best response, N (%) [95% CI]
Complete	0
Partial	6 (25) [9.8–46.7]
Stable disease	9 (37.5) [18.8–59.4]
Median TTP, months (95% CI)
All patients	5.6 (2.7–7.7)
No prior metastatic treatment	5.7 (3.7–8.3)
Median OS, months (95% CI)	13.2 (9.8–18.8)

CI confidence interval